Evidence map›Paper›PMID 33560344›Full record

ArticleThe Journal of clinical endocrinology and metabolism2021

Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes.

Jingya Wang, Jennifer M Cooper, Krishna Gokhale, Dionisio Acosta-Mena, Samir Dhalla, Nathan Byne, Joht Singh Chandan, Astha Anand, Kelvin Okoth, Anuradhaa Subramanian and 16 more

Open access · hybridFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 6 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 6 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Effects of Metformin on COVID-19 Patients with Type 2 Diabetes: A Retrospective Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023
    Article
  11. Article
  12. Review
  13. Review
  14. Diabetes and COVID-19; A Bidirectional Interplay.Frontiers in endocrinology · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Is diabetes mellitus a wrongdoer to COVID-19 severity?Diabetes research and clinical practice · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 2 countries.

Jingya WangInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Jennifer M CooperInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Krishna GokhaleInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Dionisio Acosta-MenaCegedim Health Data, Cegedim Rx, London, UK.
Samir DhallaThe Health Improvement Network (THIN), London, UK.
Nathan ByneCegedim Health Data, Cegedim Rx, London, UK.
Joht Singh ChandanInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Astha AnandInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Kelvin OkothInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Anuradhaa SubramanianInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Mansoor N BangashInstitute of Clinical Sciences, University of Birmingham, Birmingham, UK.
Thomas JacksonInstitute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
Dawit ZemedikunInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Tom TavernerInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Wasim HanifDepartment of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Sandip GhoshDepartment of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Parth NarendranDepartment of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Konstantinos A ToulisInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Abd A TahraniDepartment of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Rajendra SurenthirakumaranDepartment of Community and Family Medicine, Faculty of Medicine, University of Jaffna, Jaffna, Sri Lanka.
Nicola J AdderleyInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Shamil HaroonInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Kamlesh KhuntiDiabetes Research Centre, University of Leicester, Leicester.
Christopher SainsburyInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
G Neil ThomasInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Krishnarajah NirantharakumarInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
University of Birmingham · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBHealthcare Improvement Scotland · GBHealth Data Research UK · GBNHS Greater Glasgow and Clyde · GBUniversity of Jaffna · LKUniversity of Leicester · GB

Funding

Medical Research Council MR/V005030/1
6 · The paper itself

Abstract

objectiveDiabetes has emerged as an important risk factor for mortality from COVID-19. Metformin, the most commonly prescribed glucose-lowering agent, has been proposed to influence susceptibility to and outcomes of COVID-19 via multiple mechanisms. We investigated whether, in patients with diabetes, metformin is associated with susceptibility to COVID-19 and its outcomes. RESEARCH DESIGN AND

methodsWe performed a propensity score-matched cohort study with active comparators using a large UK primary care dataset. Adults with type 2 diabetes patients and a current prescription for metformin and other glucose-lowering agents (MF+) were compared to those with a current prescription for glucose-lowering agents that did not include metformin (MF-). Outcomes were confirmed COVID-19, suspected/confirmed COVID-19, and associated mortality. A negative control outcome analysis (back pain) was also performed.

resultsThere were 29 558 and 10 271 patients in the MF+ and MF- groups, respectively, who met the inclusion criteria. In the propensity score-matched analysis, the adjusted hazard ratios for suspected/confirmed COVID-19, confirmed COVID-19, and COVID-19-related mortality were 0.85 (95% CI 0.67, 1.08), 0.80 (95% CI 0.49, 1.30), and 0.87 (95% CI 0.34, 2.20) respectively. The negative outcome control analysis did not suggest unobserved confounding.

conclusionCurrent prescription of metformin was not associated with the risk of COVID-19 or COVID-19-related mortality. It is safe to continue prescribing metformin to improve glycemic control in patients with.

Indexed as

AgedCohort StudiesCOVID-19Diabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsKaplan-Meier EstimateMaleMetforminMiddle AgedPropensity ScoreRetrospective StudiesHypoglycemic AgentsMetforminCOVID-19metforminSARS-CoV-2 infectiontype 2 diabetes mellitus

Identifiers

PMID33560344
PMCPMC7928949
OpenAlexW3127562815

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.